Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

BACKGROUND: In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. We present findings o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C.S., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T.G., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358416/
https://www.ncbi.nlm.nih.gov/pubmed/34371381
http://dx.doi.org/10.1016/j.esmoop.2021.100189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358416/
https://www.ncbi.nlm.nih.gov/pubmed/34371381
http://dx.doi.org/10.1016/j.esmoop.2021.100189

Ejemplares similares